Role of HMGB1 in apoptosis-mediated sepsis lethality

Severe sepsis, a lethal syndrome after infection or injury, is the third leading cause of mortality in the United States. The pathogenesis of severe sepsis is characterized by organ damage and accumulation of apoptotic lymphocytes in the spleen, thymus, and other organs. To examine the potential causal relationships of apoptosis to organ damage, we administered Z-VAD-FMK, a broad-spectrum caspase inhibitor, to mice with sepsis. We found that Z-VAD-FMK–treated septic mice had decreased levels of high mobility group box 1 (HMGB1), a critical cytokine mediator of organ damage in severe sepsis, and suppressed apoptosis in the spleen and thymus. In vitro, apoptotic cells activate macrophages to release HMGB1. Monoclonal antibodies against HMGB1 conferred protection against organ damage but did not prevent the accumulation of apoptotic cells in the spleen. Thus, our data indicate that HMGB1 production is downstream of apoptosis on the final common pathway to organ damage in severe sepsis.

[1]  R. Donato,et al.  The Amphoterin (HMGB1)/Receptor for Advanced Glycation End Products (RAGE) Pair Modulates Myoblast Proliferation, Apoptosis, Adhesiveness, Migration, and Invasiveness , 2006, Journal of Biological Chemistry.

[2]  S. Joos,et al.  Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas , 2005, Gut.

[3]  C. Chung,et al.  Leukocyte apoptosis and its significance in sepsis and shock , 2005, Journal of leukocyte biology.

[4]  K. Tracey,et al.  The cytokine activity of HMGB1 , 2005, Journal of leukocyte biology.

[5]  K. Tracey,et al.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.

[6]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[7]  K. Tracey Fatal Sequence: The Killer Within , 2005 .

[8]  M. Lotze,et al.  Addicted to Death: Invasive Cancer and the Immune Response to Unscheduled Cell Death , 2005, Journal of immunotherapy.

[9]  K. Tracey,et al.  Recombinant HMGB1 with cytokine-stimulating activity. , 2004, Journal of immunological methods.

[10]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Stefan Joos,et al.  HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Peter A. Ward,et al.  Novel strategies for the treatment of sepsis , 2003, Nature Medicine.

[13]  M. Yamakuchi,et al.  High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. , 2003, Arthritis and rheumatism.

[14]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[15]  Jun Yu Li,et al.  High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. , 2002, Arthritis and rheumatism.

[16]  K. Tracey,et al.  HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. , 2002, Gastroenterology.

[17]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[18]  Derek C. Angus,et al.  Epidemiology of sepsis: An update , 2001, Critical care medicine.

[19]  R. Hotchkiss,et al.  Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte , 2000, Nature Immunology.

[20]  P. Vandenabeele,et al.  Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins. , 1999, Journal of immunology.

[21]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[22]  I. Chaudry,et al.  Melatonin administration following hemorrhagic shock decreases mortality from subsequent septic challenge. , 1996, The Journal of surgical research.

[23]  K. Tracey,et al.  HMGB1 in the immunology of sepsis (not septic shock) and arthritis. , 2004, Advances in immunology.